The HEPV RWE program enhances the use, acceptability, and incorporation of RWE by working with FDA, CMS and other payers, health technology assessment organizations, and others. Activities focus on:

  • Approaches that are scientific and methodologically rigorous for use with payers
  • Payer acceptance and adoption of RWE into coverage and health technology assessment evidence standards
  • Manufacturer awareness of RWE and capacity to develop RWE for coverage, reimbursement, and health technology assessment purposes.

The RWE Working Group

Established in 2020, the RWE Working Group oversees activities, including determining priorities, managing the work, and identifying opportunities. Jeff Farkas, Vice President of Global Health Economics, Reimbursement, and Government Affairs at Medtronic Diabetes, chairs the RWE Working Group.